Literature DB >> 18956250

Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: update on methods to reduce false tests.

G la Marca1, S Malvagia, B Casetta, E Pasquini, M A Donati, E Zammarchi.   

Abstract

We report on our 6-year experience of expanded newborn screening by tandem mass spectrometry in Tuscany (Italy), the first Italian Region to screen all newborns for more than 40 inborn errors of metabolism: organization, diseases observed and updates on methods to reduce false-positive and false-negative tests are described. Blood collection is recommended between 48 and 72 h of life. Blood spots are sent daily by courier to laboratory. When a positive result occurs, two subsequent procedures are followed: for disorders with possible acute metabolic decompensation, the baby is immediately recalled and clinical examinations and confirmatory tests are performed; for the other disorders, the nursery provides for a second blood spot. If the test is positive, clinical examinations and confirmatory tests are performed. In both cases, if confirmatory tests are positive, a treatment and a follow-up programme are started. Up to now, spots from 160 000 infants have been analysed and 80 affected patients have been identified (disorders of amino acids, organic acids and fatty acids metabolism). We describe adjustments to cut-off values, the introduction of a second-tier test for propionic acidaemia and for methylmalonic aciduria, the inclusion of succinylacetone in the panel of metabolites, and protocols for premature infants and for newborns on parenteral nutrition or transfused. These changes resulted in a reduction in recalls from 1.37% to 0.32% and consequently of working time and parental stress. Avoiding false-negatives by using more specific markers and minimizing the false-positive rate with second-tier testing is important for a successful newborn screening programme.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956250     DOI: 10.1007/s10545-008-0965-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

Review 1.  Systematic review and meta-analysis to estimate the birth prevalence of five inherited metabolic diseases.

Authors:  Sowmiya Moorthie; Louise Cameron; Gurdeep S Sagoo; Jim R Bonham; Hilary Burton
Journal:  J Inherit Metab Dis       Date:  2014-07-15       Impact factor: 4.982

2.  Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan.

Authors:  Dau-Ming Niu; Yin-Hsiu Chien; Chuan-Chi Chiang; Hui-Chen Ho; Wuh-Liang Hwu; Shu-Min Kao; Szu-Hui Chiang; Chuan-Hong Kao; Tze-Tze Liu; Hung Chiang; Kwang-Jen Hsiao
Journal:  J Inherit Metab Dis       Date:  2010-06-22       Impact factor: 4.982

3.  The national Austrian newborn screening program - eight years experience with mass spectrometry. past, present, and future goals.

Authors:  David C Kasper; Rene Ratschmann; Thomas F Metz; Thomas P Mechtler; Dorothea Möslinger; Vassiliki Konstantopoulou; Chike B Item; Arnold Pollak; Kurt R Herkner
Journal:  Wien Klin Wochenschr       Date:  2010-10-15       Impact factor: 1.704

4.  Screening and follow-up results of fatty acid oxidative metabolism disorders in 608 818 newborns in Jining, Shandong province.

Authors:  Chiju Yang; Caihong Shi; Cheng Zhou; Qiuhua Wan; Yanbin Zhou; Xigui Chen; Xianlian Jin; Chenggang Huang; Peng Xu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

5.  Heptadecanoylcarnitine (C17) a novel candidate biomarker for newborn screening of propionic and methylmalonic acidemias.

Authors:  Sabrina Malvagia; Christopher A Haynes; Laura Grisotto; Daniela Ombrone; Silvia Funghini; Elisa Moretti; Kathleen S McGreevy; Annibale Biggeri; Renzo Guerrini; Raquel Yahyaoui; Uttam Garg; Mary Seeterlin; Donald Chace; Victor R De Jesus; Giancarlo la Marca
Journal:  Clin Chim Acta       Date:  2015-09-11       Impact factor: 3.786

6.  Expanded newborn screening in New South Wales: missed cases.

Authors:  Jane Estrella; Bridget Wilcken; Kevin Carpenter; Kaustuv Bhattacharya; Michel Tchan; Veronica Wiley
Journal:  J Inherit Metab Dis       Date:  2014-06-27       Impact factor: 4.982

Review 7.  Clinical applications of gene therapy for primary immunodeficiencies.

Authors:  Maria Pia Cicalese; Alessandro Aiuti
Journal:  Hum Gene Ther       Date:  2015-04       Impact factor: 5.695

8.  Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.

Authors:  Françoise F Hamers; Catherine Rumeau-Pichon
Journal:  BMC Pediatr       Date:  2012-06-08       Impact factor: 2.125

9.  Clinical relevance of short-chain acyl-CoA dehydrogenase (SCAD) deficiency: Exploring the role of new variants including the first SCAD-disease-causing allele carrying a synonymous mutation.

Authors:  Rodolfo Tonin; Anna Caciotti; Silvia Funghini; Elisabetta Pasquini; Sean D Mooney; Binghuang Cai; Elena Proncopio; Maria Alice Donati; Federico Baronio; Ilaria Bettocchi; Alessandra Cassio; Giacomo Biasucci; Andrea Bordugo; Giancarlo la Marca; Renzo Guerrini; Amelia Morrone
Journal:  BBA Clin       Date:  2016-03-10

10.  Children who develop type 1 diabetes early in life show low levels of carnitine and amino acids at birth: does this finding shed light on the etiopathogenesis of the disease?

Authors:  G la Marca; S Malvagia; S Toni; B Piccini; V Di Ciommo; G F Bottazzo
Journal:  Nutr Diabetes       Date:  2013-10-28       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.